Aligos Therapeutics, Inc. (ALGS): Net earnings per share for the last 12 months

Symbol and logo of brand Aligos Therapeutics, Inc. (ALGS)

Combating complex liver pathologies and NASH requires a systemic approach, and this 12-month EPS trend on GURU.Markets clearly demonstrates the financial dynamics of Aligos Therapeutics (ALGS). The -6.34 mark serves as the current earnings per share indicator. The solution lies in Aligos Therapeutics (ALGS) innovations for a complete cure of hepatitis B, which are implemented by a staff of top virologists retained through a stock option program.

ALGS (Aligos Therapeutics) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/14/2026

Summary analytical data breakdowns for Aligos Therapeutics Inc. (ALGS)

- stock price and consensus target price:
Stock Price Aligos|ALGS - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Aligos Therapeutics, Inc.|ALGS - Total Company Value
- balance sheet net asset value indicators:
Book Value per Share Aligos Therapeutics|ALGS - Total Stockholders' Equity|Market Value to Book Value Ratio aligos.com|ALGS - Aggregate Asset Value
- company total debt and liquidity indicators:
Total Debt to Capital Aligos Therapeutics|ALGS - Long-Term Debt to Capital|Short-Term Debt to Equity Aligos|ALGS - Company Debts|Debts to Book Capitalization Aligos Therapeutics, Inc.|ALGS - Long-Term Debt Volume|Company Short-Term Debts Aligos Therapeutics|Quick Liquidity aligos.com
- net income and valuation multiples indicators:
ALGS - Company Net Income|Expected Profit Aligos Therapeutics|ALGS - Business Payback Period|Projected Price to Earnings Aligos|ALGS - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Aligos Therapeutics, Inc.|ALGS - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Aligos Therapeutics|ALGS - Earnings per share for the trailing year|Quarterly EPS earnings growth aligos.com|ALGS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Aligos Therapeutics
- revenue and sales proceeds data:
ALGS - Company Sales Revenue|Projected Sales Volume Aligos|ALGS - P/S Multiple|Price-to-Projected Revenue Ratio Aligos Therapeutics, Inc.
Fundamental company valuation:aligos.com (ALGS)
Manufactured products of Aligos

Trailing twelve-month net income per share measures the actual portion of income attributable to a single share after deducting all expenses. This metric allows for an assessment of capital allocation efficiency and profit generation rates. For Aligos Therapeutics (ALGS), which focuses on costly R&D in hepatology, this indicator reflects the current stage of the investment cycle. By analyzing the company's net income per share over 12 months, an investor can see the impact of innovation costs. The trend of this line determines the fundamental stability of the business during the drug development period.

Competitors of Aligos Therapeutics

Arrowhead Pharmaceuticals - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters mirumpharma.com MIRM|DVAX (Dynavax Corp) - Net earnings per share for the last 12 months|ABUS (Arbutus Biopharma Corp) - Earnings per share for the last twelve months|IVA (Inventiva Pharma) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Gyre Therapeutics Corp. GYRE|Earnings per share for the last twelve months Assembly Biosciences (ASMB)|GALT (galectintherapeutics.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) GNFT (GENFIT)|Net earnings per share (EPS TTM) DURECT Corp DRRX|BIVI - Earnings per share for the last twelve months|GLMD: Earnings per share for the last twelve months|NDRA: Net earnings per share (EPS TTM)|HEPA - Net earnings per share for the last four quarters